UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.

The global pulmonary arterial hypertension treatment market is on track to achieve significant growth over the next decade, with a projected valuation of USD 7,224.4 million by 2033. This expansion ...

San Antonio attorney Mikal Watts is among a group of lawyers that negotiated a settlement of as much as $2.2 billion to resolve claims by about 80,000 people who allege a discontinued version of the ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...

The French drugmaker laid out plans to separate its consumer division--home to brands such as Allegra, Dulcolax and IcyHot--from its innovative medicines and vaccines businesses a year ago. With its ...

GSK shares rose after the British drug major agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer. Write to Rob ...

(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...